Prestige BioPharma Limited (KRX: 950210)
South Korea
· Delayed Price · Currency is KRW 15,730
-690 (-4.20%)
Nov 18, 2024, 3:30 PM KST
Prestige BioPharma Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Revenue | 689.08 | 689.08 | 161.84 | - | - | - |
| Revenue Growth (YoY) | 325.77% | 325.77% | - | - | - | - |
| Cost of Revenue | 1,218 | 1,218 | 33.94 | 228.95 | 284.85 | 123.87 |
| Gross Profit | -528.79 | -528.79 | 127.9 | -228.95 | -284.85 | -123.87 |
| Selling, General & Admin | 45,476 | 45,476 | 58,231 | 54,422 | 16,432 | 9,564 |
| Operating Expenses | 61,709 | 61,709 | -906.28 | 122,460 | 18,099 | 12,769 |
| Operating Income | -62,238 | -62,238 | 1,034 | -122,689 | -18,384 | -12,893 |
| Interest Expense | -7,404 | -7,404 | -950.8 | -18.85 | -6.2 | - |
| Interest & Investment Income | 12,402 | 12,402 | 10,464 | 2,729 | 158.22 | 523.21 |
| Earnings From Equity Investments | - | - | -16.96 | - | - | - |
| Currency Exchange Gain (Loss) | -4,232 | -4,232 | -924.24 | -1,592 | -4,620 | 57.88 |
| Other Non Operating Income (Expenses) | 6,693 | 6,693 | 4,034 | 2,282 | 414.8 | -1,986 |
| EBT Excluding Unusual Items | -54,779 | -54,779 | 13,639 | -119,288 | -22,437 | -14,299 |
| Gain (Loss) on Sale of Investments | - | - | - | - | 15,081 | - |
| Gain (Loss) on Sale of Assets | 89.4 | 89.4 | 72.12 | 211.59 | -0.36 | - |
| Asset Writedown | - | - | -15,807 | -91,573 | - | -599.83 |
| Pretax Income | -54,689 | -54,689 | -2,095 | -210,649 | -7,357 | -14,898 |
| Income Tax Expense | 408.68 | 408.68 | 763.28 | 800.66 | 34.08 | 98.47 |
| Earnings From Continuing Operations | -55,098 | -55,098 | -2,859 | -211,450 | -7,391 | -14,997 |
| Minority Interest in Earnings | 22,177 | 22,177 | 20,428 | - | - | - |
| Net Income | -32,921 | -32,921 | 17,569 | -211,450 | -7,391 | -14,997 |
| Net Income to Common | -32,921 | -32,921 | 17,569 | -211,450 | -7,391 | -14,997 |
| Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 52 | 43 |
| Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 52 | 43 |
| Shares Change (YoY) | - | - | - | 16.46% | 20.98% | - |
| EPS (Basic) | -547.81 | -547.81 | 292.35 | -3518.53 | -143.23 | -351.60 |
| EPS (Diluted) | -547.81 | -547.81 | 292.35 | -3796.17 | -143.23 | -351.60 |
| Free Cash Flow | -68,091 | -68,091 | -108,636 | -102,336 | -16,396 | -13,761 |
| Free Cash Flow Per Share | -1133.03 | -1133.03 | -1807.71 | -1702.88 | -317.73 | -322.63 |
| Gross Margin | -76.74% | -76.74% | 79.03% | - | - | - |
| Operating Margin | -9032.13% | -9032.13% | 639.01% | - | - | - |
| Profit Margin | -4777.60% | -4777.60% | 10855.89% | - | - | - |
| Free Cash Flow Margin | -9881.47% | -9881.47% | -67125.45% | - | - | - |
| EBITDA | -45,971 | -45,971 | 12,684 | -118,822 | -16,717 | -11,708 |
| EBITDA Margin | - | - | 7837.31% | - | - | - |
| D&A For EBITDA | 16,267 | 16,267 | 11,650 | 3,867 | 1,667 | 1,185 |
| EBIT | -62,238 | -62,238 | 1,034 | -122,689 | -18,384 | -12,893 |
| EBIT Margin | - | - | 639.01% | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.